2.3 Cardiovascular (CV) Safety of Linagliptin in Patients with Type 2 Diabetes (T2D): A Pooled Comprehensive Analysis of Prospectively Adjudicated CV Events in Phase 3 Studies (376-OR)

Incidence of CV events is increased in T2D, but the potential for CV risk modulation with glucose lowering therapies is debated. We compared the incidence of CV events and CV mortality in patients with T2D treated with linagliptin (lina), a once daily DPP-4 inhibitor, with non-lina comparators (comp) in 19 double-blind RCTs (duration ≥ 12 weeks).